PT-141 (Bremelanotide)
PT-141 is a melanocortin agonist studied for central arousal signaling and MC4R-linked neurobiology.
What PT-141 (Bremelanotide) is
PT-141, also known as bremelanotide, is a cyclic melanocortin analog studied for effects on central melanocortin pathways rather than vascular PDE5 signaling. Published studies examine subjective arousal, erectile-response measurements, pharmacokinetics, tolerability, and melanocortin receptor biology. Its research profile is distinct from metabolic melanocortins because MC4R-linked CNS signaling is a major focus.
Bremelanotide has an FDA-approved counterpart, Vyleesi, for a specific approved indication and labeled route. Research-grade PT-141 powder is not Vyleesi, is not an approved drug product, is Research Use Only, and is not for human consumption. Reported ranges below describe published clinical research or approved-product contexts as reference information only.
PT-141 (Bremelanotide) has been studied in human trials, which is not true of most compounds in this library. The figures below come from that work.
How it works
PT-141 activates melanocortin receptors, especially MC4R-relevant pathways in the central nervous system. Unlike PDE5 inhibitors, its studied effects are not primarily mediated by direct peripheral vasodilation. Research models focus on hypothalamic and limbic signaling, dopamine-related arousal circuits, and downstream autonomic effects. Because melanocortin receptors are distributed across tissues, pharmacodynamic work also tracks nausea, flushing, blood pressure, and route-dependent exposure.
Who studies it, and why
PT-141 is studied by neuropharmacologists, sexual-medicine researchers, peptide chemists, and clinical pharmacology teams. Regulatory researchers distinguish approved bremelanotide products from research-grade material because formulation, labeling, and quality systems are not interchangeable.
What the research examines
These describe where the compound shows up in published work. None of them should be read as an established outcome.
How it appears in the literature
Amounts reported in published research, shown for reference. Not a protocol.
| Research context | Reported amount | Frequency | Route |
|---|---|---|---|
| Subcutaneous PT-141 clinical pharmacology study | 300 mcg – 10 mg | single study administration | subcutaneous |
| Intranasal PT-141 plus sildenafil study in men with erectile dysfunction | 7.5 mg | single crossover study administration | intranasal |
| FDA-approved bremelanotide product label context | 1.75 mg | as labeled for the approved product | subcutaneous |
Handling & storage
Research-grade lyophilized PT-141 is commonly stored cold, dry, and protected from light; reconstituted research solutions are generally refrigerated and used within the supplier's stated stability window.
Notes on combined research
PT-141 has been studied with PDE5-inhibitor contexts, but combining centrally active melanocortin signaling with other pharmacology changes safety and interpretation. Research designs should distinguish approved bremelanotide products from RUO PT-141 and should not convert clinical exposure data into personal protocols.
PT-141 (Bremelanotide) questions
Published PT-141 studies include subcutaneous and intranasal exposure ranges, and Vyleesi has its own approved label. Research-grade PT-141 is not Vyleesi and is not for human consumption.
Reconstitution examples often use 1-2 mL for 5-10 mg research vials. That only sets concentration for lab calculations.
PT-141 is not usually framed as a daily research compound in the core clinical literature. Frequency should be taken from the specific study being discussed.
A chart should keep subcutaneous study exposures, intranasal studies, and approved Vyleesi labeling in separate rows.
Clinical studies measure pharmacodynamic effects over hours after administration. Timing depends on route, formulation, and endpoint.
Bremelanotide is commonly cited around a 2-3 hour elimination half-life, though observed effects and study windows can extend beyond that.
It has been studied in combination contexts, but that is not a personal-use endorsement. RUO PT-141 should not be used as an approved drug substitute.
Read the research yourself
Verified against PubMed, one by one. A reference you cannot open is not evidence.
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.PubMed
- Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.PubMed
- Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.PubMed